The phase 2 DAVIO 2 trial of EYP-1901 met all primary and secondary endpoints in patients with wet age-related macular degeneration, EyePoint Pharmaceuticals announced in a press release.
Both doses of EYP-1901, vorolanib in sustained-release Durasert E technology, demonstrated noninferior change in best corrected visual acuity compared with aflibercept control.
“We are incredibly pleased by these highly positive phase 2 results which underscore EYP-1901’s potential as a paradigm-altering maintenance treatment for patients with wet AMD, with a positive safety profile,” Jay S.